Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models

Muhammad Zulfiqah Sadikan¹, Nurul Alimah Abdul Nasir²*, Lidawani Lambuk³, Rohimah Mohamud³, Nur Hidayah Reshidan⁴, Evon Low⁵, Saiful Anuar Singar⁶, Awis Sukarni Mohmad Sabere⁷, Igor Iezhitsa⁸,⁹ and Renu Agarwal⁸

Abstract
Diabetic retinopathy (DR), one of the leading causes of visual impairment and blindness worldwide, is one of the major microvascular complications in diabetes mellitus (DM). Globally, DR prevalence among DM patients is 25%, and 6% have vision-threatening problems among them. With the higher incidence of DM globally, more DR cases are expected to be seen in the future. In order to comprehend the pathophysiological mechanism of DR in humans and discover potential novel substances for the treatment of DR, investigations are typically conducted using various experimental models. Among the experimental models, in vivo models have contributed significantly to understanding DR pathogenesis. There are several types of in vivo models for DR research, which include chemical-induced, surgical-induced, diet-induced, and genetic models. Similarly, for the in vitro models, there are several cell types that are utilised in DR research, such as retinal endothelial cells, Müller cells, and glial cells. With the advancement of DR research, it is essential to have a comprehensive update on the various experimental models utilised to mimic DR environment. This review provides the update on the in vitro, in vivo, and ex vivo models used in DR research, focusing on their features, advantages, and limitations.

Keywords Diabetic retinopathy, Experimental models, In vitro, In vivo, Ex vivo
Background

Diabetic retinopathy (DR) is a leading cause of visual defects and blindness, and the number of cases is increasing globally. Approximately 25% of diabetes mellitus (DM) patients have been diagnosed with DR [1]. In a recent meta-analysis by Ye et al. [2], the global prevalence of DR is approximately 22%, and that of vision-threatening DR is about 6%. The prevalence is higher among the Middle East, North Africa, and Western Pacific countries. With the increasing DM population worldwide, the global prevalence of DR is expected to rise from 103.2 million in 2022 to 160.5 million by 2045 [2].

For effective management of DR, an in-depth understanding of the underlying molecular mechanisms is vital [202]. The development of newer medical therapeutic options for DR requires an in-depth investigation into molecular and morphological changes and functional outcomes. The success of these investigations, to a great extent, is determined by the choice of appropriate experimental models. Experimental models refer to investigational subjects possessing artificially induced characteristics mimicking human conditions. These experimental models could comprise of animals that are subjected to induction of disease characteristics using various methods such as chemicals or surgical procedures. Some animals naturally develop diseases sufficiently similar to those found in humans and are used as experimental models.

Considering the importance of the experimental models of DR, the key characteristics of various in vitro, in vivo, and ex vivo models commonly used in DR research are reviewed and summarised in this work. The benefits and limitations of these models are also discussed to understand their context-specific utility. PubMed and Medline search engines were used to gather publications published between 1960 and 2021. This was accomplished using a single or combination of keywords, such as diabetic retinopathy, streptozotocin, in vivo, in vitro, and ex vivo. Only full-paper publications published in English were selected for this review.

In vivo experimental models

Chemical-induced DR

Background

The most common method of inducing diabetes pharmacologically is to use STZ, a naturally occurring antibiotic in Streptomyces acromogenes, or alloxan, a pyrimidine derivative [3]. STZ and alloxan destroy the pancreatic β-cells in the islets of Langerhans to exert their diabetogenic properties. There is a wide range selection of animals (e.g., rats, mice, rabbits, cats, dogs, pigs, non-human primates, and zebrafish) that have been studied to understand diabetes development through the administration of STZ or alloxan. Despite the splendid array of animal models, rodents are commonly used [3]. This could be due to their rapid breeding rate, small size, and short life span. Moreover, they are cost-effective. It must be noted that the type of animals selected is based on the objective of particular studies. Nevertheless, to date, no animal model has been able to reproduce a complete human DR in terms of vascular and neural complications in both the early and late progression of the disease [4].

Methods of induction

STZ. STZ is a glucosamine–nitrosourea compound targeting insulin-producing β-cells in the pancreas to mimic diabetogenic properties in humans [5]. There are more than a hundred analogues known. STZ occurs in nature as a 50–50 combination of (α and β anomers) [6]. The fundamental STZ structure has been kept in approximately one-third of the analogues, although alterations include acetylation, alkylation, and nitroso group substitution. Acetyl derivatives have the same activity as their parent molecule [6]. In an early report in 1963, STZ administration at 65 mg/kg was reported to induce type 1 DM (T1DM) in rats [7]. A higher dose of STZ is required for mice, which ranges from 150 to 400 mg/kg of STZ [5]. STZ administration also has been reported to induce type 2 DM (T2DM) through multiple low-dose injections, in combination with other chemicals (such as nicotinamide), or with dietary manipulations for the induction of diabetes in rodents and dogs [5–9]. In general, STZ-induced onset hyperglycaemia occurs within 48 h post-STZ administration regardless of the dosage and the hyperglycaemic condition can be maintained for up to 22–24 months [10]. STZ direct uptake to the pancreatic β-cell is aided by the glucose transporter 2 (GLUT2) receptor [11]. STZ executes its cytotoxic effects on the pancreatic islets of Langerhans through its nitrosourea moiety, where it causes DNA alkylation [3]. Other than that, DNA damage by STZ occurs due to increased production of reactive oxygen species (ROS) and nitric oxide (NO) [11]. STZ can be administered through intraperitoneal, intravenous, or subcutaneous injection resulting in prolonged hyperglycaemia and other characteristics of diabetes, such as polyuria and polydipsia [12].

Other than rodents, several animal species such as zebrafish, rabbits, dogs, pigs, beagles, and monkeys, are sensitive to the pancreatic β-cell cytotoxic effects of STZ [12–16]. Zebrafish were usually induced with multiple STZ doses, whereas huge animals such as rabbits, dogs, and nonhuman primates were usually induced with a single dose protocol. STZ-induced zebrafish model remained in a hyperglycaemic state around 80 days after induction of diabetes [15]. In contrast, huge animals may stay in a hyperglycaemic state for more than four years post-induction [16].
In 1942, before STZ was discovered, alloxan was employed to induce diabetes in animal models \[17\]. Alloxan is a uric acid derivative directly targeting pancreatic cells \[18\]. It was first created by Wöhler and Liebig by combining uric acid and nitric acid \[19\]. McLetchie and his colleagues discovered that intravenous injection of alloxan resulted in hypoglycaemia owing to necrosis in the pancreas islets of Langerhans while researching kidney problems in rabbits \[17\]. The death of cells resulted in the release of insulin reserves, resulting in hypoglycaemia, followed by the establishment of diabetes within 24 h. Similar to STZ, alloxan can also be administered via intraperitoneal and subcutaneous injection \[19\]. While rabbits induced with alloxan usually did not change their food intake frequency, rodents induced with alloxan usually have polydipsia, polyuria, glycosuria, and hyperglycaemia, all of which are common symptoms of diabetes \[17\]. The suppression of glucokinase, an enzyme implicated in the glucose-insulin regulation system and expressed in the liver and pancreas, is triggered by a direct cell death associated with alloxan. The compound can be toxic to liver and kidney cells, although toxicity can be prevented with careful dosage. Owing to the mode of action of alloxan being specific to pancreatic β-cells, the appropriate dosage is required to avoid possible toxicity accumulated in liver and kidney cells \[20\]. Nevertheless, a diabetic induce agent by alloxan is challenging to administer to animals due to its low stability in water at room and body temperature \[17, 20\]. All diabetic animal models administered with alloxan, including mice, rats, dogs, rabbits, and pigs, have experienced damage to their pancreatic β-cells and lead to DR due to retina-induced lesions \[21–25\].

**STZ vs. Alloxan.** Due to the higher ease of use and efficacy, STZ has become the gold standard agent over alloxan in inducing diabetes in vivo. This is due to more excellent stability of the STZ compound and extremely fast result in disease progression \[26\]. Conversely, alloxan is less favourable as it produces unpredictable and inconsistent results. Therefore, it could be more efficacious \[27\]. However, unsuccessful hyperglycaemia induction in experimental animals happens. It is associated with resistance to STZ or alloxan, which may be related to hormones or genetic indifference of different species or gender \[27, 28\].

**Effects on retina**

**STZ.** The induction of this chemical has been shown to induce DR in a wide range of animals, as mentioned above, and various dose regimens have been developed, depending on the type of animals. Nevertheless, rodents remain the most preferred animal model for the characterisation of the disease and therapeutic drug investigations. These animals are favoured even more than the non-human primates owing to their ability to develop hyperglycaemia one week after a single dose of STZ administration. They have been reported to exhibit various non-proliferative DR (NPDR) features.

In the STZ-induced mice model, the retinal morphologic alterations observed were thinning of the ganglion cell layer (GCL), inner plexiform layer (IPL), outer plexiform layer (OPL), and total retinal thickness as early as 3 to 4 weeks post-STZ induction \[29\]. Other than that, there were reduced retinal ganglion cells (RGCs) with increased astrocytes number, accompanied by reactive gliosis within 4 to 6 weeks post-STZ induction \[30\]. Meanwhile, at ten weeks post-STZ induction there was thinning of the inner nuclear layer (INL) and outer nuclear layer (ONL) \[3\]. For the microvascular changes, enhanced vascular permeability, pericyte loss, and microglial changes were reported at eight weeks \[31, 32\], neovascularisation (formation of new vessels) at 16 weeks \[33\], thickening of the capillary basal lamina at 17 weeks \[34\], and increased of acellular capillaries and pericyte ghosts within 6 to 9 months of STZ induction \[10, 35, 36\]. Continuous inflammation that occurs due to chronic hyperglycaemia leads to leukostasis (leukocytes plug within vessels) \[35–38\] and is associated with increased acellular capillary formation \[35\]. Hemodynamic and electroretinogram (ERG) instability were also reported within four weeks post-STZ induction including a decrease of arteriolar and venular flow velocity with decreased diameter and shear rates \[39, 40\], a reduced total oscillatory potential (OP) and OP3 amplitudes with prolonged of implicit times OP2-3 \[41, 42\]. In contrast to Kurihara et al. \[41\] and Sasaki et al. \[42\], the majority of studies failed to demonstrate the same declined trend for amplitudes of a-/b-wave, highlighting a conflicting outcome of mice as DR animal models \[36\]. Although multiple studies have recognised STZ as a diabetogenic chemical agent, researchers have yet to demonstrate consistent evidence on the effect of STZ diabetic-induced apoptotic and loss of RGC, thus remaining the subject of concern in recent times. It is worth noting that few studies demonstrated different numbers of RGC post-diabetic induction, such as an increased RGC apoptosis after two weeks \[43\] and decreased RGC numbers within 6 to 10 weeks after STZ administration \[43, 44\], supporting the notion of inconsistent results. Contrary to the aforementioned studies, others found no profound RGC apoptosis or GCL cell loss within ten months of post-hyperglycaemia \[36, 38, 45\]. These contrasting observations may be due to different strains of mice or regimens of STZ administration.

As opposed to mice, lower doses of STZ are required to induce diabetic in rats \[5\]. Several strains of rats were used to develop the DR model, including Sprague Dawley (SD), Wistar, and Lewis. Changes in the retinal
morphology observed in rats were similar to those in mice. Thinning of the IPL and ONL were reported to be as early as four weeks post-STZ induction in SD rats [46, 47]. However, some studies also reported an increased total retinal layer thickness, which has been suggested to be due to retinal oedema [48, 49]. In fact, several authors reported retinal oedema as a retinal morphological feature of DR [50, 51]. Retinal oedema usually occurs after 12 to 16 weeks of STZ administration. Wistar and Lewis rats displayed degeneration of capillaries with the formation of pericyte ghosts within eight months of hyperglycaemia [52]. At the same time, Lewis and SD rats exhibit neuronal loss in GCL. Although the onset of retinal lesions varies with different rat strains, numerous phenotypes have been documented, including blood-retinal barrier (BRB) breakdown two weeks after diabetes onset [53], increased acellular capillaries containing degenerated intramural pericytes and apparent proliferation of endothelial cells after eight weeks [54], and thickening of basement membrane after one year [55]. Throughout the literature, studies have shown that DR development in rats has been linked to neuronal and glial damage before prominent vascular changes. It is identical to the mice model whereby progressive apoptosis and thinning of retinae were evident after 3 to 4 weeks of post-induction hyperglycaemia. Likewise, prominent gliosis with increased glial fibrillary acidic protein (GFAP) expression was observed at an early stage of four weeks of hyperglycaemia [56–58]. In addition, multiple studies also revealed a reduction of cells within GCL [52, 58, 205] and astrocytes [53, 57] and an increase of microglia [52, 58] at 4 to 6 weeks of post-STZ induction. Subsequently, other vascular events include increased acellular capillaries [52, 59], leukostasis [60], thickening of capillary basement membrane [61], and pericyte loss [58, 61] were apparent at a more extended period (4 to 8 months) post-STZ induction. Other than the morphological changes, retinal dysfunction was also observed through reduced visual-behaviour responses [62], reduced a-/b-wave [56, 59, 63] and OP amplitude [56, 59] with delayed OP [63] and increased retinal vessel diameter [203, 204], retinal oxidative stress markers [64], retinal pro-inflammatory cytokines level [65] and retinal pro-angiogenic markers [64, 65].

Besides rodents, animals of different species have been examined with various results on disease development. For instance, 3 to 4 weeks post-STZ administration, zebrafish displayed thinning of IPL and photoreceptor segment layer, damaged cone receptor, and neuronal loss [15]. In contrast, rabbits induced with a single dosage of STZ acquired retinal and retinal haemorrhages, vascular lesions, venous thrombosis, and proliferative retinopathy after 4.5 months of induction [66]. STZ-induced DR dogs exhibit retinal lesions similar to those of human DR. In an extensive study of the DR dogs model, STZ administration caused a thickening capillary basement membrane (BM) after one year, pericyte and smooth muscle cell loss after four years, and microaneurysms, acellular capillaries, and intraretinal microvascular abnormalities (IRMA)s after seven years of hyperglycaemia [16]. Numerous studies have shown that loss of pericytes and microaneurysm formation depend on age, with younger animals exhibiting the features faster than older ones [67]. STZ-induced diabetic pigs displayed enhanced BRB permeability, INL, and GCL thinning and thickening capillary BM thickening [68, 69]. Accordingly, the tight junctions in the retina were weakened [68]. Monkeys induced with STZ remain diabetic for 6 to 15 years. However, no significant ocular changes were observed [70]. They usually developed hypertension and ischemic retinopathy with cotton-wool spots, and hyperfluorescent patches usually occur once they were hypertensive.

**Alloxan.** FOT_FB mice induced with alloxan acquired pericyte and RGCs loss post one week of induction, along with microaneurysms within three weeks post induction [29]. In another study using C57/B16 mice, alloxan induction caused microglial changes (thicker cell bodies and shorter dendrites) in the retina [31]. However, Gaucher et al. [31] failed to observe neuronal apoptosis, glial activation, microaneurysm, and haemorrhage formation, as demonstrated in comparable models. Nevertheless, they observed a significant reduction in the b-wave/a-wave amplitude ratio and an increment in the OP latency period in ERG after three months of alloxan induction [31].

Contrariwise to STZ, studies of alloxan-induced DR in rat models were limited. Neovascularisation and cataracts were observed between two to nine months and a year, respectively, post-allocaxan administration [32, 71]. Pericyte ghosts, acellular capillaries, and thicker capillary BM were observed 15 months after alloxan induction [26, 71]. BRB breakdown, Müller glia growth, and endothelial enlargement were also reported with this induction model in rats [31, 72]. Five doses of alloxan within five weeks in dogs causes retinopathy comparable to DR in humans. However, dogs only acquired DR 53 to 69 months after the start of hyperglycaemia [22]. Alloxan-induced dogs developed haemorrhages, acellular capillaries, pericyte loss, and microaneurysms once DR appeared, making this a feasible model of PDR. Alloxan-induced pigs developed Müller cell contraction-promoting activity, which may be detected as early as 30 days following alloxan administration and can last up to 90 days [73]. These pigs developed cataracts [73], BRB breakdown, capillary collapse, and pericyte ghosts 60 days after receiving alloxan [44]. In contrast to dogs, the alloxan-induced pig model displayed several changes in NPDR.
The comparison of the chemical structure, mechanism of action, advantages, and disadvantages between STZ- and alloxan-induced models was described in Table 1.

Surgical-induced in vivo models

Background

One of the most extensively used methods to induce DR surgically in in vivo models is the removal of the pancreas, also known as pancreatectomy. Pancreatectomy can effectively mimic type 1 diabetes. Removing at least 90–95% of the pancreas can effectively induce hyperglycaemia in dogs [74]. Pancreatectomy was first discovered to increase blood sugar levels in dogs [75] following the invention of the complete pancreatectomy technique by Pfeiffer [76] in dogs. This technically challenging method has since been commonly used to create DR models, especially in larger animals, including cats, monkeys, and dogs.

Methods of induction

In cats’ models, pancreatectomy is usually performed with or without alloxan injection, which destroys pancreatic β-cells to induce T1DM [77]. In monkeys, the animals received insulin and oral pancreatic enzymes treatment after pancreatectomy. A detailed pancreatectomy method in the dog model has been fully described by Kumar et al. [78].

Effects on retina

Cats. Hyperglycaemia developed one to two weeks after pancreatectomy and was associated with early symptoms of DR, including thickening of the capillary BM as early as three months post-surgery [79]. Other than thickening of the capillary BM, microaneurysms were also acquired within five to six years post-surgery, followed by the development of retinal haemorrhages, capillary non-perfusion, and neovascularisation over the course of five to nine years [80]. Yet, two out of three long-term diabetic cats studied at seven years post-pancreatectomy developed only micro-aneurysms with no signs of haemorrhages or capillary non-perfusion. In contrast, the other cat showed no significant signs of DR [81].

Monkeys. Up to 94% of the alloxan-induced monkey models show no significant DR development within five years of hyperglycaemia after the surgery. It took 6 to 15 years post-surgery to develop mild blood-retinal barrier disruption [70]. Removal of the pancreas alone failed to induce DR in monkeys. However, spontaneous- or pharmacologically-induced hypertension in hyperglycaemic monkeys resulted in ischemic retinopathies [70]. Similar findings were seen in chemical-induced DR in monkeys. This suggests that retinal changes in monkeys depend on their hypertensive state, which may or may not correlate with the severity of the DR [82].

Dogs. Although dogs receiving pancreatectomy were used for DM research, there were no specific studies on the retina post pancreatectomy.

Diet-induced in vivo models

Background

A high-fat or high-calorie diet is one of the main factors that exacerbate the progression of DM and its complications [83, 84]. Past studies have extensively utilised obese- or diabetic-induced rodents as models to understand the effects of these diets on the progression of DR. Other than these diets; the galactose diet was also commonly used to mimic hyperglycaemic changes in the retina [85].

Table 1  Comparison of the chemical structure, mechanism of action, advantages and disadvantages between STZ- and alloxan-induced model

<table>
<thead>
<tr>
<th>Source</th>
<th>Streptozotocin (STZ)</th>
<th>Alloxan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Glucosamine–nitrosourea compound derived from Streptomyces achromogenes</td>
<td>Synthesised from uric acid oxidation</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>● Selective pancreatic β-cell uptake via GLUT2</td>
<td>● Selective pancreatic β-cell uptake via the GLUT2</td>
</tr>
<tr>
<td></td>
<td>● Generates ROS</td>
<td>● Inhibit glucokinase</td>
</tr>
<tr>
<td></td>
<td>● Causes DNA fragmentation</td>
<td>● Generates ROS</td>
</tr>
<tr>
<td></td>
<td>● Acts as a NO donor</td>
<td>● β-cell necrotic death</td>
</tr>
<tr>
<td></td>
<td>● Generates Adenosine triphosphate (ATP) de-phosphorylation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● β-cell necrotic death</td>
<td></td>
</tr>
<tr>
<td>Advantages</td>
<td>● Rapid simulation of natural T2DM disease progression</td>
<td>● High selective loss of pancreatic β-cell due to its inhibitory effect on glucokinase</td>
</tr>
<tr>
<td></td>
<td>● Induced diabetes remains longer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Cost-effective</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Easy handling (stable at 37 °C within one hour)</td>
<td></td>
</tr>
<tr>
<td>Disadvantages</td>
<td>● Poor standardisation</td>
<td>● Can be toxic to liver and kidney cells</td>
</tr>
<tr>
<td></td>
<td>● Carcinogenic to human</td>
<td>● May cause spontaneous regeneration of β-cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Less stable in water at room and body temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● High variability</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● High mortality</td>
</tr>
</tbody>
</table>
Methods of induction

High-fat diet (HFD). HFD induction can be given alone or together with single or multiple low doses of STZ to induce insulin resistance, diabetes, and complication. There were two types of variations of HFD, (a) high-fat diet alone or (b) high-fat diet with a combination of high-sucrose or high-fructose diet (HSHF or HFHF). These methods of induction were mainly used in rodents. The HFD contains 40–65% kcal of fat compared to 4.5-10% kcal of fat in normal pellets [86–90]. For the variation with sucrose or fructose, 20–50% of sucrose or fructose were added to the diet [87, 88]. The initial age of HFD induction also varies among studies, where it ranges as early as five weeks old [91] to 10 weeks old [89]. Rodents were either induced with STZ at the start of HFD or after 2 to 8 weeks of HFD [86, 89, 90]. The impact of the percentage of fat in the diet, the presence of sucrose and fructose, the initial age of starting the diet, induction with STZ, and the duration of the diet will influence the findings on the animal models [92].

Galactose. Engerman and Kern [85] were the first to describe the animal model of DR induced by high-galactose diet. Animals such as mice, rats, rabbits, dogs, and zebrafish, have been described to have DR-like changes with a high-galactose diet [93]. The percentage of galactose used in the literature varies from 30 to 50% [94–96]. The initial age to start the galactose diet also varies from 4 weeks in rats [95] to 6 to 18 months old in dogs [25, 94]. The duration of diet also varies as short as seven months [97] to a long period of 41 months [98].

Effects on retina

HFD. The retinal lesion developed through HFD, with or without the addition of STZ induction, has been reviewed explicitly by Clarkson-Townsend et al. [88]. In summary, the retinal morphological changes in rodents receiving HFD were mixed. Several studies showed decreased retinal layer thickness and vascular density, increased acellular capillaries formation, vascular permeability, and vascular bleeding. In contrast, there were studies showing opposite retinal morphological changes or no changes at all. Other observed changes in retinal tissues include decreased a-/b- wave, delayed OP amplitude in ERG, and increased lipid peroxidases and pro-inflammatory cytokines.

Galactose. Retinal changes observed in mice on a high-galactose diet were endothelial cell loss and increased acellular capillaries at 15 months of hypergalactosaemia [99, 100], and pericyte loss, microaneurysms, and retinal thickening at 21 months of hypergalactosaemia [99, 101]. Other changes observed include the presence of pericyte ghosts and capillary BM thickening at 18 months [4] and gliosis by 28 months of hypergalactosaemia [102]. Galactose-fed animals, however, lack the metabolic irregularities experienced in chronic hyperglycaemia and advanced DR; hence this method is of relatively lesser interest [102].

Genetic in vivo models

Background

In vivo, genetic models of DR have been used to investigate the pathogenesis and understand the treatment’s mechanism [103]. Spontaneous, strain-specific, and genetically edited mutations are among the genetic models that have been developed. Five identified DR mouse models include Ins2Akita [104], non-obese diabetic (NOD) [102], db/db (Leprdb) [105], Akimba [106], and Kimba [107]. All of these mouse models varied in the mode of inheritance, disease aetiology, pathology, and disease progression [4, 103].

Another standard genetic model for DR is the rat model, which is slightly larger than mice but manageable at a lower cost. There are six established genetic DR rat models as follows; Zucker diabetic fatty (ZDF) [108], Otsuka Long-Evans Tokushima fatty (OLETF) [109], bio breeding (BB), WBN/Kob [110], spontaneously diabetic Torii (SDT) [111], and Goto-Kakizaki (GK) [112]. They are classified as monogenic and polygenic models according to the strains. The DR rat monogenic models are ZDF, OLETF, and BB, with independent mutations that perturb different nodes of the DR disease pathway [4]. Meanwhile, the DR rat polygenic models are SDT, WBN/Kob, and GK, which demonstrated the genetic complexity of DR [4].

Types of genetic models

Ins2Akita mouse. It is a standard model with a missense mutation in the Insulin 2 gene representing T1DM [104]. It has a dominant point mutation causing a conformational change in the insulin protein, resulting in protein accumulation in pancreatic β-cells and ultimately leading to β-cell death [113, 114]. The DR onset begins as early as four weeks of age [104].

NOD mouse. Another model for T1DM is the NOD mouse, where pancreatic β-cells are destroyed by CD4+ and CD8+ cells via autoimmune response [115, 116]. It is a polygenic model with several loci associated with the disease phenotype relatively similar in humans. NOD mice suffer from infiltration of dendritic cells and macrophages in pancreatic islets leading to inflammation, hyperglycaemia, and apoptosis of insulin-producing β-cells [117, 118]. The DR onset begins when spontaneous hyperglycaemia occurs in these mice at 12 weeks of age. A higher incidence of diabetes was observed in female compared to male rats, where at 30 weeks of age, around 80% of females and only 20% of males were reported to have diabetes [118].
Lepr (db/db) mouse. Alternatively, db/db (Lepr<sup>db</sup>) mice is an option for a DR study focusing on T2DM. It carries a mutation in the leptin receptor owing to leptin receptor deficiency which develops hyperglycaemia and obesity after four to eight weeks in homozygous mice [119, 120].

Kimba mouse. The Kimba mice is a transgenic nondiabetic model of proliferative retinopathy resulting from overexpression of vascular endothelial growth factor (VEGF) driven by the rhodopsin promoter in rhodopsin-expressing cells [121, 122]. The proliferative changes that usually occur at a later stage of DR developed early in this model. Therefore, the usage of this model limits the potential research in understanding the mechanism before the proliferative stage of DR.

Akimba mouse. The Akimba model is a mouse model developed by cross-breeding Kimba mice with Ins2<sup>Akita</sup> mice. This model inherits both the hyperglycaemic changes from the Ins2Akita model and the proliferative changes seen in the Kimba model [106, 123].

ZDF rat. A missense mutation in the leptin receptor gene, Lepr, causes insulin tolerance and excessive body weight gain in the ZDF DR rat model, which is adequate for severe spontaneous type 2 diabetes [108, 124]. The hyperglycaemia onset started at six weeks of age and continues throughout time.

OLETF rat. OLETF rat was created by selective breeding of Long-Evans rats that developed obesity, hyperglycaemia, and glycosuria [125]. It possesses a mutation in the G-protein coupled receptor GPR10's initiation codon, which causes obesity and is ideal for mimicking T2DM [126]. The hyperglycaemia started at six months of age [127].

BB rat. BB rat is a monogenic DR model with a frameshift mutation in the immune-related nucleotide-binding protein gene Ian4, also known as Ian5, Iddm1, and Gimap5. This mutation causes the lymphopenia phenotype linked to auto-immune diabetes development [128–130].

WBN/Kob rat. The WBN/Kob rat is a spontaneous polygenic DR model, where the onset of hyperglycaemia appeared late, after 17 months old. This hyperglycaemia only affected male rats. Therefore, there might be the influence of sex hormones or chromosomal disorders. The diabetes appearance in this breed was suggested to be due to chronic pancreatitis [131]. Based on Mori et al. [132], chromosome 7, specifically the Pdwk1 (pancreatitis and DM in WBN/Kob locus 1) region, was thought to be affected in this breed.

SDT rats. Another polygenic DR model specifically for nonobese T2DM is SDT rats. SDT rat is a substrain of SD rat [133]. The Dmsdt1 was found to be the major gene locus responsible for pancreatic damage in this model [134]. The development of diabetes is more prominent in male rats, where glycosuria in male SDT rats appeared faster in the 20th week compared to females in the 45th week [135, 136].

GK rats. GK rat is a substrain of non-obese Wistar rat [137]. The mechanism behind the diabetes development of this model was suggested to be due to the anomaly of pancreatic IGF2 [138]. The development of diabetes is similar in male and female rats, where hyperglycaemia usually starts at four to six weeks of age [137]. The pancreas has an impaired capacity for β-cell neogenesis during the first four weeks of age, which is considered a pre-diabetic stage. The advantage of this breed is that diabetic cataracts appear late. Therefore, retinal microvasculature using fundus photography or OCT can be visualised easily [139].

Effects on retina

Ins2<sup>Akita</sup> mouse. The onset of DR appeared in the 8th week of hyperglycaemia induced by increasing retinal vascular permeability and reactive microglia [140]. By the 12th week, abnormal swelling in somas, axons, and dendrites of RGCs was reported. As a result of inflammation, an increase in acellular capillaries and leukocytes in the vascular wall was observed after 36 weeks [104]. The reduction of IPL and INL thickness resulted in lower cholinergic and dopaminergic amacrine cell expression, as evidenced in the retina after six months of hyperglycaemia [104, 141]. However, part of the rd8 mutation on crb1 gene causes no retinal thinning or retinal architecture disruption at six months of age [103]. Previous studies indicated C57B1/6N substrain (embryonic stem cells origin & mouse lines) contains the crb1 gene in homozygous form; meanwhile, C57B1/6J substrain possesses the wild type of crb1 gene [103]. The rd8 mutation in C57B1/6 N substrain may influence the retinal degeneration findings. Therefore, researchers should look into this mutation when using this model [140].

NOD mouse. In the fourth week of hyperglycaemia, NOD mice showed apoptosis of pericytes, endothelial cells, and RGCs with retinal capillary BM thickening [142]. In comparison, Azrad-Leibovich et al. [102] reported the presence of retinal oedema with the absence of microaneurysm capillary leakage as early as two weeks after hyperglycaemia onset. However, in another study by Zorrilla-Zubilete et al. [143], retinal oedema was absent at two weeks of hyperglycaemia onset. Reduced arteriole diameter was reported at three weeks of hyperglycaemia onset [144]. Similarly, Shaw et al. [145] reported vasoconstriction, degeneration of major vessels with abnormal microvessels, and disordered focal proliferation of vessels four months after hyperglycaemia onset. Other than morphology and vascular changes, increased retinal angiogenic VEGF level was also reported with this model [142].
**Lepr (db/db) mouse.** Reduction in RGCs number and increase in the total central retina, INL, and photoreceptor layer thickness were identified after six weeks of hyperglycaemia [146]. Gliosis reactivation and pericyte loss were reported at 4.5 to 13 months from the onset of hyperglycaemia [146]. There were also increased BRB breakdown, retinal capillary density, retinal angiogenic VEGF level, oxidative stress markers, and pro-inflammatory cytokines observed at 5 to 13 months of hyperglycaemia onset [147, 148]. The ERG findings showed a reduction of a-, b-, and c-waves at 24 weeks old [149]. Samuels et al. [150] observed that the reduction of the b-wave preceded the reduction of the a-wave at 16 weeks old.

**Kimba and Akimba mice.** The INL and ONL were reduced in Kimba mice at seven days postnatal [121]. By 28 days postnatal, microvascular abnormalities and capillary dropout were observed and continued until nine weeks of age, where pericyte loss was detected [151, 152]. The pericyte loss and retinal neovascularisation with diffuse vascular leakage were found in the late-stage DR, which were well-characterised by this breed [106, 153]. The Akimba mouse has leaky capillaries, tortuous vessels, and microaneurysms in the retina by 8 weeks old [106]. With disease progression, increased photoreceptor loss, decreased retina thickness, increased oedema persistence, and retinal detachment were observed [106].

**ZDF rat.** The capillary BM thickening and cell nuclear density increased at 6 to 7 months of age [154], whereas increased apoptotic capillary cells were observed after 20 weeks of age [155]. Szabó et al., 2017 [156] observed retinal oedema and microglial activation at 32 weeks of age with no retinal cell apoptosis. At an early age (6 to 7 months old), the absence of acellular capillaries and pericyte loss were reported, but both conditions then appeared at a later stage [157–159]. Lowering of b-wave amplitude in ERG was seen as early as 12 weeks of age [155].

**OLETF rat.** Microvessel-related symptoms appeared six weeks after hyperglycaemia onset, including leukocyte entrapment in the retinal microcirculation [125]. The reduction in pericytes and damage of endothelial cells were detected at three months post hyperglycaemia [131]. The increased thickness of the capillary BM, microaneurysms, capillary formation in loops, and tortuosity were also detected [125, 160]. The ERG findings of OLETF rats were prolonged latency of OP amplitude at 12.5 months old [161]. However, no acellular capillaries formation and pericyte ghosts were observed in this model [162].

**BB rat.** BB rats acquired retinal lesions such as pericyte loss, capillary degeneration, and microaneurysms by eight to eleven months old [163–165]. Meanwhile, Blair et al. [166] reported increased BRB breakdown and abnormal retinal microvasculature at eight months of age.

**WBN/Kob rat.** This breed acquired late-onset hyperglycaemia (9 to 12 months of age). Therefore, capillary BM thickening [167] and neovascularisation [168, 169] also appeared later at 14 to 24 months old. However, retinal degeneration, such as loss of rods and cones (outer retinal layer), appeared early before hyperglycaemia onset [167, 170].

**SDT rat.** Retinal detachment with fibrous proliferation, retinal ischemia with neovascularisation, leukostasis, increased number of apoptotic cells in the GCL and INL, pericyte loss, and vascular lesions were reported in aged SDT rats (after 12 months of age) [133, 171–173]. A distinguishing feature similar to retinal detachment observed in humans was the formation of massive retinal folds with significant leakage around the optic disc [133, 171–173]. However, the absence of microaneurysms makes them a more suitable model for studying NPDR.

**GK rat.** An increase in BRB permeability was reported by three months old, followed by an increase in the endothelial/pericyte ratio at seven months old [139, 174]. Retinal microvascular cells apoptosis, higher acellular capillary formation, and pericyte loss occurred even in mild hyperglycaemic GK rats at one year old [175]. Additionally, retinal layer thickening and reduced a- and b-waves amplitude in ERG were reported at 12 months old [176]. Retinal angiogenic markers (VEGF and matrix metalloproteinase (MMPs)) were noted to be increased by seven months old of age and not earlier than that [177, 178].

**In vitro model**

Since pathological retinal angiogenesis is the main reason for progression in DR, most in vitro cell culture utilises isolated endothelial cells to mimic human angiogenic processes [179]. The most commonly used retinal endothelial cells are bovine retinal endothelial cells (BRECs) [180], human retinal endothelial cells (HRECs) [181], and Rhesus monkey retinal and choroid endothelial cells (RF/6a) [182]. However, some studies also utilised non-retinal specific endothelial cells and focused on the angiogenesis process. The non-retinal specific endothelial cells used include human umbilical vein endothelial cells (HUVECs) [183], human microvascular endothelial cells (HMVECs) [184], and human dermal microvascular endothelial cells (HMVEC-D) [185]. The cells were treated with high glucose concentrations, imitating a diabetic condition. The target mechanism is in vitro studies using endothelial cells is an angiogenic process. Therefore, the commonly assessed markers include growth factors such as VEGF, extracellular matrix proteins such as MMPs, and signalling pathways involving oxidative stress, inflammation, and apoptosis.
Other cell types used in the in vitro model were specific retinal cells, such as pericytes, fibroblasts, macrophages, and Müller or other glial cells [186]. Glial cells are important neuronal tissue supporters, which assist communication between vessels and neurons. Studies using glial cells usually explore the relationship between vasculopathy and neuropathy in DR [53]. Among all the glial cells, Müller cells were commonly used in studying DR [187]. The disadvantage of in vitro culture is the absence of a retinal microenvironment that can be found in vivo model [188].

Ex vivo models
For ex vivo models of DR, studies usually used organotypic retinal explant cultures to mimic the structure of the tissues nearer to in vivo environment, overtaking some of the constraints of the in vitro studies [189]. Most studies using retinal explant models did research on assessing the toxicity of potential new chemicals or drugs [190] or evaluating retina functionality [191]. The initial concept of using retinal explants to investigate proliferative retinopathy was initiated by Forrester et al. [192], where bovine retinal explants cultured in collagen gels were used. Currently, the use of collagen was replaced by synthetic Matrigel, which improved vessel sprouting [189] and provided consistent results. This replacement was also recommended by the international consensus [193]. Other than bovine, mice retinal explant cultures were commonly used to study neovascularisation [194]. Vitreoretinal angiogenesis progression can also be identified using time-sequential imaging in an ex vivo model [195]. Until present, retinal explants are normally cultured with stimuli that portray the retinal environment in DR, such as high glucose, oxidative stress, or advanced glycation end-products (AGE) [196]. Other than that, the retina from the in vivo DR model was used for the ex vivo in vitro culture once the retinal neovascularisation development had taken place to represent the PDR process [197–200]. The use of retinal explants still needs to be improved in research, possibly due to the expertise requirements to isolate retinas and their unsuitability for long-term experimental periods [201].

Conclusions and perspectives
Experimental models of DR are used to study the pathophysiology, mechanisms, and potential treatments for the disease. These models aim to replicate the key features and progression of DR observed in humans. Among all the experimental models, in vivo model is most preferable due to several limitations of in vitro and ex vivo models, such as the absence of a retinal microenvironment and complex retina isolation, respectively. The in vivo model has the most significant advantage, as it can closely mimic DR-like human conditions. Among in vivo models, chemically induced diabetes by STZ is the most commonly used in vivo model. Although experimental models can be used to predict disease mechanisms or in potential treatment, they may not accurately be translated to human conditions as they do not fully replicate the complexity and heterogeneity of the disease seen in humans. However, the use of specific experimental models may target particular mechanism which is limited in human due to the limitation of the sample. Therefore, the researchers must choose an appropriate experimental DR model to address their research objectives.

Following findings from experimental models, clinical studies involving human subjects, such as clinical trials and observational studies, is vital to provide essential evidence that considers the genetic and environmental factors that influence disease pathophysiology, progression, and response to therapies. Clinical studies also ensure that the findings from experimental models are rigorously evaluated and their clinical implications are thoroughly understood. In summary, while experimental models of DR provide crucial insights into the underlying mechanisms and aid in developing treatment strategies, clinical validation is necessary to ensure the findings can be translated into meaningful outcomes for patients.

List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>Advanced glycation end-products</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BB</td>
<td>Biobreeding</td>
</tr>
<tr>
<td>BBR</td>
<td>Blood-retinal barrier</td>
</tr>
<tr>
<td>BMCECs</td>
<td>Bovine retinal endothelial cells</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DR</td>
<td>Diabetic retinopathy</td>
</tr>
<tr>
<td>ERG</td>
<td>Electroretinogram</td>
</tr>
<tr>
<td>GCL</td>
<td>Ganglion cell layer</td>
</tr>
<tr>
<td>GFAT2</td>
<td>Glutamine-fructose-6-phosphate amidotransferase</td>
</tr>
<tr>
<td>GK</td>
<td>Goto-Kakizaki</td>
</tr>
<tr>
<td>GLUT2</td>
<td>Glucose transporter 2</td>
</tr>
<tr>
<td>HFD</td>
<td>High-fat diet</td>
</tr>
<tr>
<td>HFHF</td>
<td>high-fat/high-fructose</td>
</tr>
<tr>
<td>HMVEC-D</td>
<td>Human dermal microvascular endothelial cells</td>
</tr>
<tr>
<td>HMVECs</td>
<td>Human microvascular endothelial cells</td>
</tr>
<tr>
<td>HRECs</td>
<td>Human retinal endothelial cells</td>
</tr>
<tr>
<td>HUVECs</td>
<td>Human umbilical vein endothelial cells</td>
</tr>
<tr>
<td>INL</td>
<td>Inner nuclear layer</td>
</tr>
<tr>
<td>IPL</td>
<td>Inner plexiform layer</td>
</tr>
<tr>
<td>IRMAs</td>
<td>Intraretinal microvascular abnormalities</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>NOD</td>
<td>Non-obese diabetic</td>
</tr>
<tr>
<td>NR4A1</td>
<td>Nuclear receptor 4A1</td>
</tr>
<tr>
<td>OLETF</td>
<td>Otsuka Long-Evans Tokushima fatty</td>
</tr>
<tr>
<td>ONL</td>
<td>Outer nuclear layer</td>
</tr>
<tr>
<td>OP</td>
<td>Oscillatory potential</td>
</tr>
<tr>
<td>OPL</td>
<td>Outer plexiform layer</td>
</tr>
<tr>
<td>PDR/NPDR</td>
<td>Proliferative/non-proliferative diabetic retinopathy</td>
</tr>
<tr>
<td>Rac1</td>
<td>Ras-related C3 botulinum toxin substrate 1</td>
</tr>
<tr>
<td>RF/6a</td>
<td>Rhesus monkey retinal and choroid endothelial cells</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>SDT</td>
<td>Spontaneously diabetic Tori</td>
</tr>
<tr>
<td>STZ</td>
<td>Streptozotocin</td>
</tr>
<tr>
<td>T1DM/T2DM</td>
<td>Type 1/Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>ZDF</td>
<td>Zucker diabetic fatty</td>
</tr>
</tbody>
</table>


58. Kador PT, Takahashi Y, Akagi Y, Blessing K, Randazzo J, Wyman M. Age-depen-


69. Beigrezaei S, Ghiasvand R, Feizi A, Iraj B. Relationship between dietary pat-


76. Beigrezaei S, Ghiasvand R, Feizi A, Iraj B. Relationship between dietary pat-


149. Bogdanov P, Corraliza L, Villena A, Carvalho J, Garcia-Arumi AR, Ramos J,